HDAC9 and medulloblastoma: Other clinical trials are ongoing, including testing CX-4945 drug (silmitasertib sodium), an orally bioavailable, highly selective and potent CK2 inhibitor, in children with recurrent SHH (NCT03904862), and fimepinostat, a synthetic, orally-available, small molecule that potently inhibits the activity of HDAC and PI3 kinase enzymes in recurrent medulloblastoma (NCT03893487).